Key Highlights
● Cash was CHF 210.3 million, or about $252.0 million, at Sept. 30, 2026.
● The company said its cash runway extends into the second half of 2029.
● The nine-month net loss was CHF 57.1 million, versus CHF 75.4 million.
● An R&D Day is set for Dec. 8, with a dry eye readout near year-end.
Oculis Holding AG (NASDAQ:OCS) enters a dense stretch of clinical and corporate events with a funding position that may shape how investors interpret each of them. The Swiss ophthalmology and neuro-ophthalmology company reported cash of CHF 210.3 million, or about $252.0 million, at Sept. 30, 2026, and said that runway extends into the second half of 2029. With a dry eye readout expected around year-end and an R&D Day scheduled for Dec. 8, the durability of that cash may matter as much as the data itself. The company also presents at a LifeSci investor event on Nov. 16.
Latest Company Context
In its Nov. 3 third-quarter update, Oculis reported a quarterly net loss of CHF 18.2 million. Nine-month net loss was CHF 57.1 million, compared with CHF 75.4 million a year earlier, an improvement driven mainly by a Fair Value gain on Warrant liabilities rather than lower spending. Research and Development expense rose to CHF 15.1 million in the quarter from CHF 14.1 million, and general and administrative expense increased to CHF 8.6 million from CHF 6.4 million, reflecting headcount and share-based compensation.
Cash declined only modestly from CHF 213.0 million at the end of 2025 because the company sold ordinary shares through its at-the-market program, which partly offset operating burn and currency effects. Share premium rose to CHF 607.8 million from CHF 551.7 million during 2026, indicating the scale of Equity raised. Third-quarter spending growth was concentrated in both research and overhead lines.
Key Business and index Drivers
The runway assumption supports two registrational efforts at once. Licaminlimab, a topical anti-TNF-alpha candidate for TNFR1-mediated dry eye disease, completed randomisation of 176 patients in the PREDICT-1 trial, with topline results expected around year-end 2026. Privosegtor, a neuroprotective candidate, is enrolling patients in the global PIONEER-1 registrational trial in optic neuritis, and the company expects IND clearance for acute multiple sclerosis relapses in the fourth quarter.
Oculis also completed its purchase of Assets from Accure Therapeutics, securing rights to privosegtor and an early preclinical neurology candidate. Running parallel late-stage programs raises cost, and rising R&D and G&A suggest spending is trending upward. The reliance on at-the-market sales means existing holders have been absorbing gradual dilution to maintain the cash balance, a common trade-off for clinical-stage companies. Chief Executive Riad Sherif described the third quarter as notable progress across the late-stage pipeline.
What Investors Should Watch
The R&D Day on Dec. 8 in New York may provide updated program timelines and potentially clearer indications of how spending could evolve as trials expand. PREDICT-1 topline results, expected around year-end, represent a binary clinical event whose outcome could influence both the company's priorities and its ability to raise Capital on favourable terms. IND clearance for privosegtor in acute MS relapses, guided for the fourth quarter, would open an additional indication. Investors may also watch for any change to the runway guidance into the second half of 2029, the pace of at-the-market issuance, and presentations at the Piper Sandler conference from Dec. 1 to 3 and the J.P. Morgan Healthcare Conference from Jan. 11 to 14, 2027. A positive or negative PREDICT-1 result could also change the calculus around future at-the-market sales.
A Runway That Outlasts the Catalysts
Oculis has built a cash position that, on management's estimate, outlasts its near-term catalysts, though the balance has been sustained partly by ongoing equity sales. That cushion may reduce immediate financing pressure around the dry eye readout, but spending is rising as two registrational programs advance. The coming weeks could clarify whether the runway guidance holds as the pipeline expands, and how the company intends to fund development if trial outcomes reshape its priorities. Clinical outcomes, rather than accounting gains, are likely to drive that assessment.






Please wait processing your request...